Antibody production services market seen reaching $11.45 billion by 2030

The antibody production services market is projected to grow from $6.44 billion in 2025 to $7.24 billion in 2026, then climb to $11.45 billion by 2030. Demand is being driven by chronic disease prevalence, biologics pipelines, outsourcing by drugmakers and broader use of antibody-based diagnostics and therapies.

Why it matters: - The antibody production services market is growing quickly because it supports research, diagnostics and drug development. - Rising demand for monoclonal antibodies, personalized medicine and biologics is expanding the need for external antibody production capacity. - Chronic disease growth is adding pressure for earlier detection, monitoring and targeted therapies.

What happened: - The Business Research Company released a forecast report on the global antibody production services market on October 30, 2026. - The market is projected to rise from $6.44 billion in 2025 to $7.24 billion in 2026, a CAGR of 12.4%. - The market is forecast to reach $11.45 billion by 2030, with a CAGR of 12.1%. - North America held the largest market share in 2025. - Asia-Pacific is expected to post the fastest growth during the forecast period.

The details: - Antibody production services create polyclonal or monoclonal antibodies targeted to specific antigens. - The services support detection, measurement or neutralization of proteins or pathogens in research, diagnostics and therapeutics. - Growth in the recent period was driven by biomedical research expansion, rising monoclonal antibody demand, broader diagnostic use, higher life sciences investment and advances in antibody engineering. - Future growth is expected to come from personalized medicine demand, expanding biologics pipelines, more pharmaceutical outsourcing, improved antibody formats and stronger reproducibility and quality control. - Key trends include customized antibody generation, greater use of recombinant antibody technologies, a push for high-affinity and high-specificity antibodies, more outsourced production and tighter quality validation standards. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The 2026 report package includes market attractiveness scoring, total addressable market analysis, company scoring matrix graphics and tables, Excel dashboards, market hotspots infographics and updated technology and trend analysis. - The Business Research Company also offered a free sample of the report at sample request and the full market report.

Between the lines: - The forecast points to a market shifting from broad research use toward more specialized, outsourced and regulated production models. - The emphasis on reproducibility, validation and quality control suggests buyers are prioritizing reliability as antibody applications expand into clinical and diagnostic settings. - Chronic disease prevalence remains a structural demand driver because it increases the need for testing, monitoring and precision treatment. - In June 2024, the UK National Health Service reported 3,615,330 people were diagnosed with non-diabetic hyperglycemia or pre-diabetes in 2023, up 18% from 3,065,825 in 2022.

What's next: - Market growth is expected to continue through 2030 as drugmakers expand biologics pipelines and increase outsourcing. - Demand should rise for customized, recombinant and higher-specificity antibody production services. - Regional competition is likely to intensify as Asia-Pacific grows faster than other markets. - The Business Research Company positioned its 2026 report set around strategic intelligence tools, suggesting continued focus on market segmentation and buyer decision support.

The bottom line: - Antibody production services are moving from a niche research input to a larger strategic layer in diagnostics and therapeutics, with double-digit growth expected through 2030.